poisar

Stocks · News reference

BTIG Reiterates Sell on Ginkgo Bioworks Holdings, Maintains $5 Price Target

Benzinga Newsdesk

BTIG analyst Mark Massaro reiterates Ginkgo Bioworks Holdings (NYSE:DNA) with a Sell and maintains $5 price target.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

DNA
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Bcc Research

    AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors

    Artificial intelligence is accelerating vaccine adjuvant discovery and optimization, with over $140M in disclosed funding signaling a structural market shift. Major investments include Pfizer and NVIDIA's $80M joint venture into CytoReason and Ginkgo Bioworks' $31M contract with SaponiQx. AI tools are addressing key bottlenecks in antigen-adjuvant optimization and immune response prediction, supported by government initiatives globally. However, regulatory fragmentation, infrastructure gaps, and a shortage of AI-immunology talent remain challenges.

    PFENVDADNAIMDCY